Related Experiment Video
Updated: May 29, 2026
07:06
Pentylenetetrazole-Induced Kindling Mouse Model
Published on: June 12, 2018
Lamotrigine is favourable for startle-induced seizures
Hiroko Ikeda1, Katsumi Imai, Hitoshi Ikeda
1National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan. hirikeda@szec.hosp.go.jp
Epileptic Disorders : International Epilepsy Journal with Videotape
|September 8, 2011
Summary
Startle-induced seizures (SISs) can cause injury and are often resistant to standard treatments. Lamotrigine (LTG) as an add-on therapy showed significant seizure control improvement in some patients with SISs, potentially preventing falls.
Area of Science:
- Neurology
- Clinical Neuroscience
- Epileptology
Background:
- Startle-induced seizures (SISs), often triggered by auditory stimuli, pose a significant risk of injury due to falls.
- Conventional antiepileptic drugs are frequently ineffective for managing SISs, necessitating exploration of alternative therapeutic strategies.
Observation:
- A case series of six patients with SISs was treated with lamotrigine (LTG) as an adjunctive therapy.
- Three patients experienced significant seizure reduction, one had milder seizures, and two showed no improvement; one patient developed a rash.
Findings:
- Adjunctive lamotrigine (LTG) therapy demonstrated potential efficacy in managing startle-induced seizures (SISs).
- Significant improvements in seizure frequency and severity were observed in a subset of patients, leading to a less restricted daily life.
- LTG may help prevent injuries associated with falls from SISs.
Implications:
- Lamotrigine (LTG) represents a potential therapeutic option for managing refractory startle-induced seizures (SISs).
- Further research into LTG's efficacy and safety for SISs is warranted.
- Successful treatment of SISs with LTG could improve patient quality of life by reducing fall-related injuries.
More Related Videos
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...